Curve Therapeutics Ltd. has raised £40.5 million (US$51.2 million) in a series A round to take two lead programs toward the clinic over the next three years. Since its formation in 2019, Curve has applied its Microcycle intracellular screening platform to discover a pipeline of small molecules against oncology targets that have evaded conventional approaches.